|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.46 USD | +1.19% |
|
-1.69% | -5.59% |
Business description: Protagonist Therapeutics, Inc.
Number of employees: 128
Sales by Activity: Protagonist Therapeutics, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 28.63M | 27.36M | 26.58M | 60M | 434M |
Geographical breakdown of sales: Protagonist Therapeutics, Inc.
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 28.63M | 27.36M | 26.58M | 60M | 434M |
Executive Committee: Protagonist Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 2008-11-30 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 2022-04-17 |
Newman Yeilding
CTO | Chief Tech/Sci/R&D Officer | - | 2025-01-01 |
Samuel Saks
CTO | Chief Tech/Sci/R&D Officer | 71 | 2019-05-07 |
Arturo Molina
CTO | Chief Tech/Sci/R&D Officer | 67 | 2022-11-06 |
Composition of the Board of Directors: Protagonist Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 2008-11-30 |
Harold Selick
CHM | Chairman | 71 | 2014-03-18 |
William Waddill
BRD | Director/Board Member | 68 | 2016-06-30 |
Lewis Williams
BRD | Director/Board Member | 76 | 2017-06-07 |
Bryan Giraudo
BRD | Director/Board Member | 49 | 2018-05-15 |
Sarah O'Dowd
BRD | Director/Board Member | 76 | 2020-08-11 |
Company details: Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
94560-1160, Newark
+
http://www.protagonist-inc.com
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.19% | -1.69% | +113.24% | +409.96% | 5.16B | |
| -0.50% | +5.21% | -8.92% | -5.43% | 48.77B | |
| +2.54% | +0.40% | +53.71% | +52.92% | 39.27B | |
| -0.21% | +4.62% | +36.37% | +68.00% | 36.05B | |
| -1.50% | -9.87% | -14.99% | -25.16% | 27.89B | |
| +4.46% | +4.82% | +147.38% | +293.16% | 19.45B | |
| +1.12% | +18.33% | +31,885.82% | +4,335.23% | 15.61B | |
| +1.03% | +3.06% | +35.14% | -3.78% | 13.78B | |
| +3.28% | -0.35% | +55.06% | +91.52% | 13.71B | |
| +0.94% | -3.48% | +162.11% | +110.78% | 13.18B | |
| Average | +1.41% | +1.33% | +3,246.49% | +532.72% | 23.29B | |
| Weighted average by Cap. | +1.11% | +1.47% | +2,177.91% | +350.92% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PTGX Stock
- Company Protagonist Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition